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1. Introduction
The potential role of Human cytomegalovirus (hCM) infection in promoting neoplasia is an
active area of scientific research. [1] Although still controversial, there is a growing body of
evidence that links hCMV infection to a variety of malignancies, including those of the breast,
prostate, colon, lung and brain (gliomas). [2-7] hCMV induces alterations in regulatory
proteins and non-coding RNA that are associated with a malignant phenotype. These changes
promote tumour survival by effecting cellular proliferation, invasion, immune evasion, and
production of angiogenic factors [8] Constant immune surveillance governs the destruction of
the majority of cancer cells and precancerous conditions in the human body. However, the
most pathogenic of malignant tumors acquire immune evasion strategies which render them
less vulnerable to destruction by immune cells.
The characteristic hallmarks of a malignant cell include:
1. sustaining proliferative signaling and evading growth suppressors,
2. resisting cell death and enabling replicative immortality,
3. inducing angiogenesis, activating invasion and metastasis. [9]
In cancers which are not attributable to infectious agents, chronic inflammation may also play
a critical role in the transition from a precancerous condition to invasive malignancy. Inflam‐
mation is the seventh hallmark of neoplasia (Table 1). [10] During chronic inflammation,
certain “promoters,” such as hepatitis C virus and Epstein-Barr virus (EBV), may facilitate the
transformation of a pre-malignant condition to neoplasia. [11,12] Cancer “promoters” are
agents that, by themselves, may not have a significant oncogenic impact on normal cells but
can drive precancerous cells towards neoplasia.
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1. Sustaining proliferative signaling
2. Evading growth suppressors
3. Resisting cell death
4. Inducing angiogenesis
5. Activating invasion and metastasis
6. Enabling replicative immortality
7. Tumor-promoting inflammation
Table 1. The “seven” hallmarks of cancer
2. Chronic inflammation and oncogenesis
Associations linking chronic infection, chronic inflammation and malignancy have been well
chronicled. [13] As many as 25% of all cancers can be traced to chronic infection or other types
of chronic inflammation. [14] Infectious agents that cause chronic inflammation promote
oncogenesis by complex pathways, and are depicted in Figure 1. Key mediators of inflamma‐
tion-induced oncogenesis include generation of mutagenic chemical mediators such as
reactive oxygen and nitrogen species, genetic variations in inflammatory cytokines [15], and
creation of a micro-environment with features of chronic inflammation such as nuclear factor
kappa B (NF-κB). [16,17] In such conditions, tumor-associated macrophages (TAMs) play a
pivotal role in mediating inflammatory (M1) responses, as well as immunosuppressive and
growth (M2) responses. [18]
M2-polarized TAMs and the related myeloid-derived suppressor cells are key components of
smoldering inflammation that drives neoplastic progression. The M2 responses, while
important for wound healing, can promote neoplastic transformation. TAMs respond to
cytokines such as Interleukin (IL)-10 and Transforming Growth Factor (TGF)-β, acquiring M2
properties that promote immune suppression by blocking dendritic cell (DC) maturation and
attracting regulatory T-cells (T-regs). [19,20] T-regs are potent inhibitors of the T-cell anti-
tumor response. [21]
Activation of NF-κB pathway mediated by COX-2 and IL-6 via STAT-3 transcriptional
activation also promotes malignant transformation. [22] NF-κB is a transcription factor that
mediates an inflammatory cascade leading to generation of COX-2, an inducible isoform of
nitric oxide synthase (iNOS) and the inflammatory cytokines IL-1β, IL-6, and Tumor Necrosis
Factor (TNF) -α. These cytokines, in conjunction with nitric oxide produced by TAMs and
tumor cells, are present in high concentration in the tumor microenvironment and are
important promoters of inflammation-driven oncogenesis and immunosuppression. [23-25]
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3. Concept of oncomodulation
Tumor cells have aberrations in cell cycle signaling, RNA transcription and the production of
tumor-suppression proteins. The concept of “oncomodulation” suggests that a virus may
modulate cellular pathways [26] through changes to viral regulatory proteins and noncoding
RNA which eludes to tumor cell properties (cell proliferation, survival, invasion, production
of angiogenic factors, and immune evasion). hCMV not only promotes oncogenesis but also
contributes to a more malignant tumor cell phenotype (Figure 2). While investigators have
long postulated a role for hCMV in human neoplasia, many of the early studies were not
reproducible and lacked clear in situ histopathological correlations with the proposed diseases.
[27,28] The concept of “hit-and-run” oncogenesis holds that infection with hCMV takes place
during an earlier time frame to tumour development. hCMV infection sets into motion
processes resulting in malignancy, but the virus is no longer detectable by the time cancer
occurs. [29] Several of the more important cellular pathways that could lead to cancer and
which are modulated by hCMV are reviewed below.
3.1. Resistance to apoptosis
Resistance to apoptosis is a common feature of cancer cells. [9,30,31] Early research on hCMV
infection revealed that hCMV protects the fibroblasts it infects from apoptosis. hCMV
immediate early (IE) proteins (e.g., IE2-86 & IE2-72) [32] are able to prevent adenovirus E1A
Figure 1. Pathway linking chronic inflammation and oncogenesis. (Adapted from Schetter et. al. [13])
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protein-induced apoptosis-by both p53-dependent and independent mechanisms- of hCMV
infected fibroblasts. Direct anti-apoptotic activity of hCMV proteins is related to defined
transcripts encoded by the hCMV UL36-UL37 genes. [33,34] The product of the UL36 gene is
an inhibitor of caspase activation which binds to the pro-domain of caspase-8 and inhibits Fas-
mediated apoptosis. [35] Similarly, the UL37 gene product, UL37 exon 1, is a mitochondrial
inhibitor of apoptosis and inhibits the recruitment of the pro-apoptotic proteins Bax and Bak
to mitochondria, resulting in their functional inactivation. [36] hCMV further protects tumor
cells from apoptosis by the induction of cellular proteins, including AKT, Bcl-2, and ΔNp73α.
[37] Induction of the anti-apoptotic protein Bcl-2 by hCMV, results in acquired resistance to
cytotoxic drugs such as cisplatin and etoposide. This resistance can be reversed after treatment
with the anti-hCMV drug, ganciclovir. [37] Engagement of platelet derived growth factor
receptor (PDGFR) α or virus co-receptors (including integrins and Toll-like receptor-2) by
hCMV glycoproteins can also lead to activation of mitogen-activated protein kinase (MAPK)
and/or phosphatidyl-inositol 3-kinase (PI3-K) pathways that can alter apoptotic responses
(Figure 3). [38-40]
3.2. Cancer cell adhesion, migration and invasion
Adhesion of cancer cells to endothelium is critical in promoting metastases. [41-43] hCMV can
facilitate this process by promoting activation of integrins (e.g., β1α5 and B1) on the tumor cell
surface, and by increasing adhesion of tumor cells to the neighboring endothelium. Tumor cell
adhesion to endothelium is also facilitated by activation of integrin-linked kinases (e.g.,
phosphorylation of focal adhesion kinase Tyr397). [4,,44] Down regulation of adhesion
molecule receptors by hCMV (e.g., neural cell adhesion molecule, CD56), causes a focal
disruption of endothelial cells facilitating tumor cell transmigration. [1,45] The net effects of
hCMV on adhesion molecules account for decreased binding of cancer cells to each other and
Figure 2. Concept of Oncomodulation. (Adapted from Michaelis et. al. [99])
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increased binding to endothelium, which is an important early process in formation of
metastasis.
3.3. Angiogenesis
Angiogenesis is the growth of the new blood vessels and is essential for growth of malignant
tumors. [9,46] Through the technique of secretome analysis researchers have shown that
proteins secreted from hCMV-infected cells contain increased levels of pro-angiogenic
molecules, and increased pro-angiogenic activity in cell-free supernatants. [47] US28 is a hCMV
protein seen in high concentrations in the supernatant. This particular protein alters adhesion
properties of epithelial cells inducing a pro-angiogenic and transformed phenotype through
up-regulation of vascular endothelial growth factor (VEGF). [48] Additional supernatant
proteins, including IE1-72 and IE2-86, increase vascular smooth muscle cell migration,
proliferation, and expression of PDGF-β receptor. Furthermore, IE2-86 promotes endothelial
proliferation by binding and inactivating the tumor oncogene p53 in endothelial cells. [49,50]
Expression of IL-8, another well-recognized promoter of tumor angiogenesis, is increased by
hCMV via transactivation of IL-8 promoter through the cellular transcription factors NF-κB
and AP-1. [51] Binding of hCMV to and signaling through integrin β1, integrin β3, and
epidermal growth factor receptor can also promote angiogenesis. [47,52]
Figure 3. Major signaling pathways activated by hCMV that contribute to oncomodulation by hCMV. (Adapted from
from Michaelis et. al. [100])
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Expression of thrombospondin (TSP-1), a potent inhibitor of angiogenesis, is suppressed in
several hCMV-infected cancer cell lines, suggesting yet another mechanism by which hCMV
can promote increased angiogenesis and a more malignant phenotype. [53,54] hCMV -
mediated activation of COX-2 may also promote angiogenesis in tumor cells by inducing
expression of Fibroblast Growth Factor (FGF), VEGF, PDGF, iNOS, and TGF-α, and by
promoting capillary endothelial cell migration and tube formation (Figure 3). [55]
3.4. Impact of hCMV on cell cycle
In hCMV-infected host cells, viral regulatory proteins induce cell cycle arrest and prevent
cellular DNA replication, whilst replication of viral DNA remains enabled. [8,56] While some
hCMV regulatory proteins can induce cell cycle arrest, others can promote cell cycle progres‐
sion. [57,58] hCMV IE2-86 induces cell cycle arrest by activating ataxia telangiectasia mutated
(ATM) gene-dependent phosphorylation of p53, leading to p53- and p21-dependent inhibition
of cell cycle progression. [59] In contrast, the hCMV regulatory proteins IE1-72, IE2-86, and the
tegument proteins pp71 and UL97 interact with and deactivate proteins of the Rb family,
promoting entry into S-phase of the cell cycle. [60]
The cell cycle of neoplastic cells is inherently dysfunctional. [9,31] In precancerous or trans‐
formed cells, the function of virus regulatory proteins may depend on the replicative status of
the cell. [61,62] The hCMV protein US28 promotes cell cycle progression and cyclin D1
expression in cells with a neoplastic phenotype; whereas, it induces apoptosis in non-neo‐
plastic cells. [48] Persistent hCMV infection of tumor cells may lead to a selection of virus
variants with changes in virus regulatory proteins that have lost their ability to induce cell
cycle arrest. [63,64]
4. Escape of immune surveillance by cancer cells: Role of hCMV
Immunological tolerance is a process by which the immune system no longer recognizes an
aberrant antigen as “foreign.” [67] Through “natural” or “self-tolerance” the body does not
mount an immune response to self-antigens. “Induced tolerance” to external antigens can be
created by manipulating the immune system. Mechanisms of tolerance that exist to prevent
autoimmune disease may also preclude the development of an adequate antitumor response.
[65-67] This concept of “immune tolerance” may be particularly important in malignancies
whose etiology is associated with inflammation. [68] Expression of hCMV proteins by infected
tumor cells may induce ‘immune tolerance’ to tumor cells. Also, several tumor-derived factors
contribute to the emergence of complex local and regional immunosuppressive networks,
including VEGF, IL-10, TGF-β, and prostaglandin E-2 (PGE2). [66,69]
hCMV has evolved multiple strategies for immune evasion resulting in persistent viral
infection in the host [70-74] Several hCMV proteins, including those expressed with IE genes,
block the host cell MHC class I antigen expression, which is essential for activation of CD8+
T-lymphocyte anti-tumor cytotoxicity. hCMV UL83 protein (pp65) blocks antigen presentation
of hCMV epitopes to CD8+ T-cells, and expression of hCMV UL18, a MHC class I homologue,
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disrupts “natural killer” (NK) cell recognition of hCMV-infected cells. [75] Disruption of
hCMV antigen presentation by infected cells is mediated by hCMV protein US3, which
sequesters MHC class I complexes in the endoplasmic reticulum, and hCMV protein US11
which causes dislocation of the MHC class I heavy chain from the cytoplasm. [76-78] hCMV-
encoded IL-10 homologue impairs tumor antigen presentation by inhibiting maturation,
normal differentiation and cytokine production of dendritic cells and macrophages.. [79-81]
hCMV induces integrin αvβ6 expression in endothelial cells of blood vessels in different tissues,
causing activation of TGF-β1, resulting in interference of host immune responses against tumor
cells by blocking the activation of lymphocytes and monocyte derived phagocytes. [82] These
direct immune-modulatory effects of hCMV on myeloid cells within the tumor microenvir‐
onment, along with expression of immunosuppressive cytokines provide a virtually impass‐
able environment for the host anti-tumor immune system.
5. Influence of CMV on tumor microenvironment
Persistent hCMV infection of non-neoplastic cells in the tumor microenvironment leads to a
paracrine secretion of inflammatory molecules that promote malignancy. [83] The secretome
of hCMV-infected fibroblasts contains exceedingly high levels of growth factors, matrix
remodeling proteins such as matrix metalloproteinases (MMPs), and angiogenic factors that
signal through the TGF-β pathway. [47,84] These paracrine-secreted factors are also able to
activate latent growth factors. PDGFs acts as strong mitogens and their overexpression is
important in the pathogenesis of multiple malignancies. [85-87] In addition to growth factors,
high levels of many ECM modifiers such as MMPs, tissue inhibitors of metalloproteinases
(TIMPs) and urokinase receptor (uPAR) secreted by hCMV infected cells aiding, tumor
invasion and metastasis. [84]
6. DNA mutations, impaired DNA repair mechanisms and epigenetic
changes by hCMV that leads to genomic instability
hCMV infection can drive neoplastic transformation by causing chromosome damage and
genetic instability in infected cells, particularly in vulnerable adult stem cells. [88-90] hCMV
in combination with cytotoxic chemotherapy agents synergistically increases genotoxic effects.
[91,92] The virus can induce specific chromosome 1 strand breaks at positions 1q42 and 1q21
in a replication-independent fashion, both of which are associated with DNA repair and
replication genes. [89,93,94] hCMV IE1-72 and IE2-86 proteins when in conjunction with other
viral oncogenic proteins (e.g., adenovirus E1A protein) that disrupt cell cycle can induce
oncogenic transformation. [29]
hCMV can contribute to genomic instability through a variety of different pathways. In brief,
the virus may induce chromosomal aberrations (e.g., production of micronuclei, misaligned
chromosomes, chromosomal lagging and bridging) by hCMV UL76 protein. [95,96] The virus
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can also disrupt DNA repair pathways, including the activity of ATM and ATM-Rad3 (ATR).
[97] More recently, hCMV has been shown to modulate oncogenesis through the telomerase
pathway by activating human telomerase reverse transcriptase (hTERT) in fibroblasts and
malignant cells. [98]
7. Conclusions
Significant advances have been made in understanding the roles of chronic inflammation,
tumor microenvironment, cancer stem cells, tumor immunology, and infectious agents in the
pathobiology of cancer. Several clinical and experimental findings suggest that hCMV may
play a role in promoting certain cancers. In cells that are persistently infected with hCMV, the
expression of viral proteins may prevent the immune system from identifying or removing
these cells, thereby offsetting immune detection of transformed cells. The effects of hCMV in
promoting tumor cell immune evasion may prove important in development of cancer
immunotherapies, particularly if the hCMV-infected cells are resistant to the action of cytolytic
peptides released by activated NK and cytotoxic T-cells. Also, if viral proteins that inhibit
apoptosis are expressed by hCMV infected tumour cells, the cancer cells may be less suscep‐
tible conventional chemotherapeutic agents. Whether hCMV is ultimately established as an
oncogenic virus will require additional research in the areas of virology, epidemiology and
molecular oncology, and systematic refinement of the concept of “oncomodulation.” Insights
into the role of hCMV in oncogenesis may increase understanding of cancer biology and
promote development of novel therapeutic strategies.
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